SGK
NVO

Steigerwald Gordon & Koch’s Novo Nordisk NVO Stock Holding History

Steigerwald Gordon & Koch’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Sell
414
-120
-22% -$5.16K ﹤0.01% 447
2026
Q1 		$19.6K Hold
534
– – ﹤0.01% 431
2025
Q4 		$27.2K Sell
534
-170
-24% -$8.69K ﹤0.01% 406
2025
Q3 		$39.1K Buy
+704
New +$41.2K ﹤0.01% 340

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Steigerwald Gordon & Koch's NVO Position: Q2 2026 in Review

Steigerwald Gordon & Koch reduced its Novo Nordisk (NVO) stake by 22% in Q2 2026, selling an estimated $5.16K and leaving 414 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #447.

Steigerwald Gordon & Koch first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $39.1K in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Steigerwald Gordon & Koch held 414 shares of Novo Nordisk worth $19.8K as of Q2 2026.
  • Steigerwald Gordon & Koch sold 120 Novo Nordisk shares in Q2 2026, an estimated $5.16K.
  • Novo Nordisk made up ﹤0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #447 holding.
  • Steigerwald Gordon & Koch first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
  • Steigerwald Gordon & Koch's Novo Nordisk position peaked at $39.1K in Q3 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.